by EmpathiCSubstanceS | Nov 8, 2020 | Psychedelic Medicine
NEW YORK, Sept. 24, 2020 /PRNewswire/ — Last year may have been all about cannabis, but it’s clear that 2020 and beyond belongs to the psychedelic medicine market. Ever since Johnson & Johnson’s (NYSE:JNJ) ketamine-derived medicine, Spravato,...
by EmpathiCSubstanceS | Nov 8, 2020 | Psychedelic Medicine
Fifty years after political and cultural winds slammed shut the doors on psychedelic research, UC Berkeley is making up for lost time by launching the campus’s first center for psychedelic science and public education. With $1.25 million in seed funding from an...
by EmpathiCSubstanceS | Nov 8, 2020 | Psychedelic Medicine
On May 7, 2019, the city of Denver made headlines for becoming the first U.S. city to effectively decriminalize psilocybin mushrooms through its passing of Initiated Ordinance 301 (I-301). In the months that followed, Oakland and Santa Cruz followed suit,...
by EmpathiCSubstanceS | Nov 8, 2020 | Psychedelic Medicine
Psilocybin has been fast-tracked by the FDA to become a prescription medication in psychedelic-assisted therapy for depression, but now we’re seeing investors line up to support a new indication for the synthetic compound that’s been made famous—in its organic form—by...
by EmpathiCSubstanceS | Nov 8, 2020 | Psychedelic Medicine
A new study is presenting the first published data from preliminary human trials investigating the effect of psilocybin-assisted psychotherapy to treat major depressive disorder (MDD). The incredibly positive results have been described as just a “taste of things to...
